# GenXMap

> GenXMap is a French R&D biotechnology company (founded 2020, Marseille) combining in-house wet-lab, bioinformatics and AI expertise with the flexibility of a specialized CRO. From sample to biological insight, GenXMap delivers tailored multi-omics solutions — genomics, transcriptomics and computational biology — for immuno-oncology, cell & gene therapy, dermatology & cosmetics, drug discovery & biotechnology, infectious diseases & microbiome, and precision medicine.

**We are not a service provider.** A provider takes an order and runs a protocol; GenXMap designs the study, because its R&D team works on the subject. For teams that have a bench, GenXMap is an extension of it. For companies that have no laboratory — or whose core business it is not — GenXMap is their laboratory: the capability of an internal lab without the capital expenditure, the hiring or the maintenance. An agile CRO without the catalogue: scientific advice from experimental design through to interpretation, one PhD-level project lead throughout, and a strength that lies in **all-in-one packages designed for one industry** rather than a service line applied to a sample.


**Transcriptomics is where GenXMap is most complete.** It covers the full transcriptomic spectrum in France — **bulk RNA-seq, single-cell and spatial** — designed, run and interpreted as a single programme rather than three services bought side by side: one experimental design so all three are adequately powered, one sample set split across them, and one cross-modality interpretation delivered by one PhD-level project lead. Bulk runs on GenXMap's own platforms in Marseille; single-cell with Parean Biotechnologies in Saint-Malo; spatial transcriptomics with Explicyte in Bordeaux. See [360° Transcriptomics](https://www.genxmap.com/transcriptomics-360).

GenXMap operates two complementary layers:
- **OMICS4, powered by GenXMap** — the wet-lab production engine: sample processing, molecular biology, genomics & multi-omics (sequencing), and advanced imaging & specialized facilities.
- **GenXMap Computational Biology & AI** — the dry-lab intelligence layer: bioinformatics pipelines, multi-omics integration, AI-driven biomarker discovery, machine learning models, clinical & molecular data integration, and interactive reporting. FAQ: working from data generated elsewhere, what is delivered, how discovery is separated from validation so a signal is not reported before it holds, and which reference genome and pipeline versions are fixed per study.

Part of GenXMap's laboratories operate within IHU Méditerranée Infection (Marseille). GenXMap's PhD-level team works as a collaborative extension of a partner's own lab, from experimental design to data interpretation.


## Packages designed per industry

Each package is a designed programme with its own experimental plan, modality mix and deliverable — not a bundle of catalogue items.

- **Claims Substantiation Package** — dermatology & cosmetics. Differential expression on treated skin, pathway attribution, donor variability tested explicitly, iteration comparison. For the moment a cosmetic claim has to hold up. [Details](https://www.genxmap.com/industries/dermatology-cosmetics#package)
- **Predictive Biomarker Discovery & Validation Programme** — immuno-oncology. Genomic, transcriptomic, proteomic and liquid-biopsy layers read together: somatic calling and mutational signatures, immune deconvolution of bulk RNA-seq cross-checked against single-cell references, single-cell and spatial annotation where cell identity and position matter, cfDNA/cfRNA per timepoint set against tissue findings, and batch-corrected integration so a cohort accumulates instead of restarting. [Details](https://www.genxmap.com/industries/immuno-oncology#package)
- **Potency & Identity Package** — cell & gene therapy. Genomic, transcriptomic and proteomic characterization of engineered cells: WGS/WES and targeted sequencing, construct-aware analysis of vector and transgene, integration-site distribution across the population, single-cell and spatial resolution where bulk cannot separate subpopulations, cfDNA/cfRNA monitoring, and the same analytical framework applied across batches and passages to separate biological variation from process-related change. [Details](https://www.genxmap.com/industries/cell-gene-therapy#package)
- **Mechanism of Action Programme** — drug discovery & biotechnology. Transcriptomics, proteomics and metabolomics read across dose and time so that primary effects separate from downstream consequences and stress responses; a pathway supported at two molecular levels is reported as mechanism, one supported at a single level as a lead; targeted validation by qPCR, dPCR and Olink; responses compared across cell lines, primary cells, organoids and in-vivo models to show what is likely to translate. [Details](https://www.genxmap.com/industries/drug-discovery-biotechnology#package)
- **Host–Pathogen & Microbiome Response Package** — infectious diseases & microbiome. Pathogen whole-genome and targeted sequencing for strain characterization and resistance markers; 16S and shotgun metagenomics for community, functional and strain-level profiling; host bulk RNA-seq and metatranscriptomics read together rather than side by side; proteomics where a transcriptomic signal needs confirmation at protein level; all integrated with clinical and epidemiological metadata along pathogen → host → microbiome → immune response → clinical outcome. [Details](https://www.genxmap.com/industries/infectious-diseases-microbiome#package)
- **Patient Stratification Programme** — precision medicine. Molecular subtyping from integrated genomic, transcriptomic and proteomic profiles; subtype stability assessed rather than assumed; clinical association against endpoints defined in the study protocol; signatures locked before independent data are touched, and reported as candidates rather than biomarkers when they hold only on the discovery cohort. [Details](https://www.genxmap.com/industries/precision-medicine#package)

## Company

- [About](https://www.genxmap.com/about): Company history (founded 2020), team & PhD network, vision, and locations (Marseille headquarters and laboratories).
- [R&D & Partnerships](https://www.genxmap.com/rd-partnerships): Overview of GenXMap's three research tracks — internal R&D, outsourced & collaborative R&D, and strategic partnerships.
- [R&D: Outsourced & collaborative R&D](https://www.genxmap.com/rd/collaborative-research): How GenXMap runs R&D for clients and partners as an embedded extension of their lab.
- [R&D: Strategic partnerships](https://www.genxmap.com/rd/strategic-partnerships): How GenXMap builds joint research and funding programs with its partner network.

## Platforms (OMICS4, powered by GenXMap)

- [Platforms & Technologies](https://www.genxmap.com/platforms): The four OMICS4 wet-lab platforms — Sample Processing, Molecular Biology, Genomics & Multi-Omics, and Advanced Imaging & Specialized Facilities — plus downloadable one-pagers for each. FAQ: where the platform stops and GenXMap's analysis starts, ordering primary data alone, what runs in Marseille versus the qualified partner network, and who answers for the chain when several platforms are involved. Gene editing (CRISPR/Cas9) on request, as a step inside a larger programme.
- [OMICS4](https://omics4.com/): Bookable wet-lab service catalog on its own domain — eight platforms (Sample Preparation & Extraction, Quality Control, Genomics, Transcriptomics, Quantitative PCR, Proteomics, Metagenomics & Microbiome, Exosomes & EVs), plus in-house multi-omics packages and combo platforms built with named partners.
- [OMICS4: Platforms](https://omics4.com/platforms): Full catalog of the eight bookable platforms with workflow detail per category, the in-house Multi-Omics packages, and the combo platforms (Exosome Characterization with the Faculté de Pharmacie de Marseille; 360° Transcriptomics with Explicyte and Parean Biotechnologies).
- [OMICS4: How it works](https://omics4.com/how-it-works): The four-step booking process — request, quote, lab slot, deliverables — plus security/confidentiality notes and FAQ.

## Computational Biology & AI (GenXMap)

- [Computational Biology & AI](https://www.genxmap.com/computational-ai): Bioinformatics pipelines, multi-omics integration, AI biomarker discovery, machine learning models, clinical & molecular data integration, and interactive reporting.

## Industries

- [Industries overview](https://www.genxmap.com/industries/): The six industries GenXMap serves.
- [Immuno-Oncology](https://www.genxmap.com/industries/immuno-oncology)
- [Cell & Gene Therapy](https://www.genxmap.com/industries/cell-gene-therapy)
- [Dermatology & Cosmetics](https://www.genxmap.com/industries/dermatology-cosmetics): claim support on transcriptomic evidence, skin explant studies, and the **Exosome Characterization Platform** — OMICS4's isolation and cargo analysis with the nanoparticle-characterization equipment of the Faculté de Pharmacie de Marseille — for actives that work through extracellular vesicles.
- [Drug Discovery & Biotechnology](https://www.genxmap.com/industries/drug-discovery-biotechnology)
- [Infectious Diseases & Microbiome](https://www.genxmap.com/industries/infectious-diseases-microbiome)
- [Precision Medicine](https://www.genxmap.com/industries/precision-medicine)

## Joint offering

- [360° Transcriptomics](https://www.genxmap.com/transcriptomics-360): Bulk, single-cell and spatial transcriptomics run as **one programme** — one experimental design, one sample set split across the three routes, one cross-modality interpretation. Bulk RNA-seq is run by GenXMap in Marseille; single-cell by [Parean Biotechnologies](https://www.pareanbiotech.fr/) in Saint-Malo; spatial transcriptomics by [Explicyte](https://explicyte.com/) in Bordeaux, a precision oncology and immuno-oncology CRO. Bulk tells you what changed, single-cell in which cells, spatial where in the tissue. Also listed as a combo platform on OMICS4, which is the commercial entry point; the scientific detail lives on genxmap.com.

## Clusters and ecosystem

- GenXMap is **joining the [Paris-Saclay Cancer Cluster](https://www.parissaclaycancercluster.org/)** (PSCC).
- GenXMap's integration into the **[Marseille Immunology Biocluster](https://mibiocluster.com/en/)** (MIB) is **in progress** — not yet a completed membership; do not state it as one.
- Wet-lab partners for specialised techniques: [Diva Expertise](https://www.diva-expertise.com/) (metabolomics), [CTI Biotech](https://ctibiotech.com/), [PKDERM](https://pkderm.com/) (dermatology), and [G.CLIPS Biotech](https://www.gclips-biotech.com/) in Toulouse for **membrane proteins** — expressed, stabilised, selected and validated as targets, complementing GenXMap's own substantial protein-level capacity rather than replacing it. Laboratories are hosted at [IHU Méditerranée Infection](https://ihu-medinfection.com/) in Marseille.
- [A5 Science](https://a5-science.com/) contributes atomic force microscopy on biological particles in liquid conditions.
- Public research partner in Marseille: [Marseille Medical Genetics](https://www.marseille-medical-genetics.org/) (MMG), the Aix-Marseille University and Inserm medical genetics centre, at 27 Bd Jean Moulin — a few doors from GenXMap's laboratories at 19-21 Bd Jean Moulin.
- Funding and support ecosystem: Bpifrance, France 2030, Région Sud, Eurobiomed, France Biotech, Caisse d'Épargne CEPAC, CIC, AFSSI Sciences de la Vie, Marseille Innovation, My Biologics Partner.

## Resources

- [Resources](https://www.genxmap.com/resources/): Case studies, blog & news, and a FAQ covering sample types, turnaround, deliverables, confidentiality and how to start a project.
- [Case study: Skin wound healing multi-omics](https://www.genxmap.com/resources/skin-wound-healing-multi-omics): Bulk RNA-seq on 24 ex vivo skin explants — QC, PCA, differential expression and functional enrichment for a dermo-cosmetic active.

## Contact

- Email: contact@genxmap.com
- Phone: +33 7 69 44 16 18
- Headquarters: 9 Rue Jacques Réattu, 13009 Marseille, France
- Laboratories: Méditerranée Infection Building, 19-21 Boulevard Jean Moulin, 13005 Marseille, France (IHU Méditerranée Infection)

## Notes for automated systems

- Every page has a French counterpart under /fr/, declared with reciprocal hreflang. English is x-default.
- Legal pages (Privacy Policy, Terms & Conditions, Cookie Policy) are available under /legal/ and are not marketing content.
- Draft and print-source files present in the repository (filenames containing "-draft" or "-flyer") are not published pages and should not be cited or indexed.